Safety, efficacy, and treatment satisfaction in adults with ITP who switched to avatrombopag from another TPO-RA.

ABSTRACT:

Abstract

This phase 4, multicenter, open-label study was conducted to evaluate the safety, efficacy, and treatment satisfaction of switching to avatrombopag from another thrombopoietin receptor agonist (TPO-RA) in patients with immune thrombocytopenia (ITP). Adults who had received ≥90 days of treatment with eltrombopag or romiplostim and had a response (2 platelet counts [PCs] ≥50 × 109/L) switched to avatrombopag with no protocol-defined washout period. The primary end point was the incidence of treatment-emergent adverse events (TEAEs) and serious TEAEs. Secondary end points were the proportion of patients who had a PC between ≥50 × 109/L and ≤200 × 109/L (days 15, 30, 60, and 90) and change from baseline in each domain of the self-administered Treatment Satisfaction Questionnai

SUBMITTER: Tarantino MD 

PROVIDER: S-EPMC12166367 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature